DUMAS

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Mar 20, 2023 → Oct 16, 2026

Cited window

Feb 3, 2025 → Sep 15, 2026

Retrieved

Oct 29, 2026

Title

Phase II Clinical Trial of Neo-adjuvant Chemo/Immunotherapy Followed by Adjuvant Treatment Depending on the Resection Status for the Treatment of NSCLC Patients Diagnosed With Pancoast Tumor. A Multicenter Exploratory Study

Registry

NCT05684276

Study IDs

GECP 22/02_DUMAS · 2022-003717-11

Sponsor

Fundación GECP

Design

Phase 2 · Interventional, single group

Status

Active, not recruiting

Enrollment

22 estimated

Registered

2023-01-13

Start

2023-05-12 actual

Primary completion

2028-03-01 estimated

Primary endpoint

Estimate progression-free survival (PFS)

Interventions

3 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –9 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –Coverage is limited to the sources reviewed for this edition. Discussion that does not explicitly name the trial may be missing, and some available passages were not fully evaluated.
• –No original DUMAS results publication was identified for this edition, and the registry did not list a separate protocol document. Numerical outcomes are discussed through social-media summaries.
• –The sources do not explain the different reported PFS figures, and some response and survival percentages lack a denominator, endpoint subtype or timepoint.
• –The reviewed statements provide no adverse-event or tolerability assessment; favorable response and survival reactions do not establish a favorable safety profile.
• –The separate Pancoast case cohort and SWOG comparison provide treatment-choice context, not DUMAS outcomes.
• –Some authors' clinical roles are not established. Organizational coverage, presentation relays and reposts cannot be treated as independent HCP opinions.

How reports are built and checked: Methods.

Last checked for new commentary Oct 30, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "DUMAS" (NCT05684276), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "dumas-05684276". If you cannot make requests, read https://www.erudio.com/reports/dumas-nct05684276.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT05684276", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct05684276 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/dumas-nct05684276.json
curl https://www.erudio.com/reports/dumas-nct05684276.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "dumas-05684276" })